HAUPPAUGE, N.Y. , April 09, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced its DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies has been selected for
Features the Multiplex Zika, Chikungunya, Dengue System HAUPPAUGE, N.Y. , April 08, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics , Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced a second $1.5 million purchase order from UNICEF for
IgM/IgG Antibody Results in 15 Minutes from a Simple Finger Stick HAUPPAUGE, N.Y. , March 31, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the U.S.
HAUPPAUGE, N.Y. , March 20, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in accordance with Nasdaq Listing Rule 5635(c)(4), it has granted a restricted stock unit award to Richard
HAUPPAUGE, N.Y. , March 20, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced its receipt of a $4 million order from Bio-Manguinhos for the purchase of Chembio’s DPP COVID-19 IgM/IgG System,
HAUPPAGE, N.Y., March 12, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Richard Eberly as its President and Chief Executive Officer effective March 16, 2020 . Mr.
HAUPPAUGE, N.Y. , March 12, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2019 .
Chembio Management to Discuss During Earnings Call on March 12, 2020 HAUPPAUGE, N.Y. , March 12, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that it has entered into a worldwide
Rare Diseases Therapeutic Division Funds Phase II MEDFORD, N.Y. , March 11, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it successfully completed the technical feasibility phase
MEDFORD, March 03, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2019 after the close of trading on Thursday,
Print Page